WallStSmart

Lineage, Inc. Common Stock (LINE)vsSeritage Growth Properties (SRG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 34376% more annual revenue ($5.36B vs $15.55M). SRG leads profitability with a 0.0% profit margin vs -2.7%. LINE earns a higher WallStSmart Score of 36/100 (F).

LINE

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

SRG

Avoid

24

out of 100

Grade: F

Growth: 2.0Profit: 2.5Value: 4.0Quality: 7.5
Piotroski: 6/9Altman Z: -0.63
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LINE.

SRGSignificantly Overvalued (-53.5%)

Margin of Safety

-53.5%

Fair Value

$1.98

Current Price

$2.63

$0.65 premium

UndervaluedFair: $1.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

SRG2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Debt/EquityHealth
1.013/10

Elevated debt levels

SRG4 concerns · Avg: 2.5/10
Market CapQuality
$149.82M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-25.9%2/10

ROE of -25.9% — below average capital efficiency

Revenue GrowthGrowth
-98.4%2/10

Revenue declined 98.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : SRG

The strongest argument for SRG centers on Price/Book, Debt/Equity.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : SRG

The primary concerns for SRG are Market Cap, Profit Margin, Return on Equity.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while SRG is a value play — different risk/reward profiles.

LINE is growing revenue faster at 0.4% — sustainability is the question.

SRG generates stronger free cash flow (-6M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LINE scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm dedicated to regenerative medicine, focusing on next-generation cell therapies targeting ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust strategic collaborations, Lineage is at the forefront of developing transformative treatment options that aim to improve patient outcomes significantly. The company's commitment to enhancing its diverse product pipeline and expediting clinical trials makes it an attractive investment opportunity for institutional investors seeking exposure in the rapidly evolving healthcare landscape.

Visit Website →

Seritage Growth Properties

REAL ESTATE · REAL ESTATE SERVICES · USA

Seritage Growth Properties is a publicly traded, self-managed and self-managed REIT with 166 wholly owned properties and 29 unconsolidated properties totaling approximately 30.

Want to dig deeper into these stocks?